Piotr Suwalski1, Mariusz Kowalewski2, Marek Jasiński3, Jakub Staromłyński4, Marian Zembala5, Kazimierz Widenka6, Mirosław Brykczyński7, Jacek Skiba8, Michał Oskar Zembala5, Krzysztof Bartuś9, Tomasz Hirnle10, Inga Dziembowska11, Zdzisław Tobota12, Bohdan J Maruszewski12. 1. Clinical Department of Cardiac Surgery, Central Clinical Hospital of the Ministry of Interior and Administration, Warsaw, Poland; Clinical Department of Cardiac Surgery, Centre of Postgraduate Medical Education, Warsaw, Poland. 2. Clinical Department of Cardiac Surgery, Central Clinical Hospital of the Ministry of Interior and Administration, Warsaw, Poland; Cardiothoracic Research Centre, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland. Electronic address: kowalewskimariusz@gazeta.pl. 3. Department and Clinic of Cardiac Surgery, Wroclaw Medical University, Wroclaw, Poland. 4. Clinical Department of Cardiac Surgery, Central Clinical Hospital of the Ministry of Interior and Administration, Warsaw, Poland. 5. Department of Cardiac, Vascular, and Endovascular Surgery and Transplantology, School of Medicine, Medical University of Silesia, Katowice, Poland; Division of Dentistry in Zabrze, Medical University of Silesia, Katowice, Poland; Division of Cardiac Surgery, Heart and Lung Transplantation and Mechanical Circulatory Support, Silesian Center for Heart Disease, Zabrze, Poland. 6. Clinical Department of Cardiac Surgery, District Hospital No. 2, University of Rzeszów, Rzeszów, Poland. 7. Department of Cardiac Surgery, Pomeranian Medical University, Szczecin, Poland. 8. Department of Cardiac Surgery, 4 Military Clinical Hospital Centre for Heart Diseases, Wroclaw, Poland. 9. Department of Cardiovascular Surgery and Transplantology, Jagiellonian University, John Paul II Hospital, Krakow, Poland. 10. Department of Cardiosurgery, Medical University of Bialystok, Bialystok, Poland. 11. Department of Pathophysiology, Faculty of Pharmacy, Collegium Medicum, Nicolaus Copernicus University, Toruń, Poland. 12. Department of Pediatric Cardiothoracic Surgery, The Children's Memorial Health Institute, Warsaw, Poland.
Abstract
OBJECTIVES: Surgical ablation for atrial fibrillation (AF) performed at the time of other valvular- or nonvalvular cardiac procedure is a mainstay of therapy; yet the data regarding its influence on remote survival are sparse. We aimed to evaluate late survival in patients undergoing mitral valve (MV) surgery with concomitant surgical ablation for AF. METHODS: Procedure-related data from the Polish National Registry of Cardiac Surgery Procedures (Krajowy Rejestr Operacji Kardiochirurgicznych) were retrospectively collected. A total of 11,381 patients with baseline AF (46.6% men; mean age 65.6 ± 9.0 years) undergoing MV surgery between 2006 and 2017 in 37 reference centers across Poland and included in the registry were analyzed. Median follow-up was 5 years (mean, 4.6 years; interquartile range, 1.9-7.9 years). Cox proportional hazards models were used for computations. Propensity score matching for the comparison of MV + ablation versus MV alone was performed. RESULTS: Of included patients, 2449 (21.5%) underwent surgical ablation for AF. Patients in this group were significantly younger (63.8 ± 8.7 years vs 66.1 ± 9.0 years; P < .001) and were at lower baseline surgical risk (EuroSCORE, 2.86 vs 3.69; P < .001). During the 12-year study period, there was a significant survival benefit (hazard ratio, 0.71; 95% confidence interval, 0.63-0.79; P < .001) for MV + ablation compared with MV alone. After rigorous propensity matching (logit model, 1784 pairs) surgical ablation was associated with nearly 20% improved survival (hazard ratio, 0.82; 95% confidence interval, 0.70-0.96; P = .011). Benefit of surgical ablation was maintained in subgroup analyses, yet most benefit was appraised in low-risk patients such as those with EuroSCORE of 2 to 5 or age < 50 years. CONCLUSIONS: Concomitant surgical ablation for AF in patients undergoing mitral valve procedures is safe, feasible, and significantly improves late survival.
OBJECTIVES: Surgical ablation for atrial fibrillation (AF) performed at the time of other valvular- or nonvalvular cardiac procedure is a mainstay of therapy; yet the data regarding its influence on remote survival are sparse. We aimed to evaluate late survival in patients undergoing mitral valve (MV) surgery with concomitant surgical ablation for AF. METHODS: Procedure-related data from the Polish National Registry of Cardiac Surgery Procedures (Krajowy Rejestr Operacji Kardiochirurgicznych) were retrospectively collected. A total of 11,381 patients with baseline AF (46.6% men; mean age 65.6 ± 9.0 years) undergoing MV surgery between 2006 and 2017 in 37 reference centers across Poland and included in the registry were analyzed. Median follow-up was 5 years (mean, 4.6 years; interquartile range, 1.9-7.9 years). Cox proportional hazards models were used for computations. Propensity score matching for the comparison of MV + ablation versus MV alone was performed. RESULTS: Of included patients, 2449 (21.5%) underwent surgical ablation for AF. Patients in this group were significantly younger (63.8 ± 8.7 years vs 66.1 ± 9.0 years; P < .001) and were at lower baseline surgical risk (EuroSCORE, 2.86 vs 3.69; P < .001). During the 12-year study period, there was a significant survival benefit (hazard ratio, 0.71; 95% confidence interval, 0.63-0.79; P < .001) for MV + ablation compared with MV alone. After rigorous propensity matching (logit model, 1784 pairs) surgical ablation was associated with nearly 20% improved survival (hazard ratio, 0.82; 95% confidence interval, 0.70-0.96; P = .011). Benefit of surgical ablation was maintained in subgroup analyses, yet most benefit was appraised in low-risk patients such as those with EuroSCORE of 2 to 5 or age < 50 years. CONCLUSIONS: Concomitant surgical ablation for AF in patients undergoing mitral valve procedures is safe, feasible, and significantly improves late survival.
Authors: Aneta Mela; Elżbieta Rdzanek; Łukasz A Poniatowski; Janusz Jaroszyński; Marzena Furtak-Niczyporuk; Małgorzata Gałązka-Sobotka; Dominik Olejniczak; Maciej Niewada; Anna Staniszewska Journal: Front Pharmacol Date: 2020-09-08 Impact factor: 5.810
Authors: Mariusz Kowalewski; Marek Jasiński; Jakub Staromłyński; Marian Zembala; Kazimierz Widenka; Mirosław Brykczyński; Jacek Skiba; Michał Zembala; Krzysztof Bartuś; Tomasz Hirnle; Inga Dziembowska; Piotr Knapik; Zdzisław Tobota; Bohdan Maruszewski; Piotr Suwalski Journal: PLoS One Date: 2020-04-22 Impact factor: 3.240
Authors: Patrick M McCarthy; James L Cox; Olga N Kislitsina; Jane Kruse; Andrei Churyla; S Chris Malaisrie; Christopher K Mehta Journal: J Clin Med Date: 2021-12-31 Impact factor: 4.241
Authors: Ju Youn Kim; Dong Seop Jeong; Hee-Jin Kwon; Seung-Jung Park; Kyoung-Min Park; June Soo Kim; Young Keun On Journal: J Korean Med Sci Date: 2021-11-08 Impact factor: 2.153
Authors: Radosław Litwinowicz; Piotr Mazur; Piotr Śliwiński; Magdalena Bryndza; Krzysztof Bartuś; Grzegorz Filip; Artur Bartoszcze; Jacek Piątek; Janusz Konstanty-Kalandyk; Mariusz Kowalewski; Krithika Ramaprabhu; Hubert Hymczak; Bogusław Kapelak; Anna Kędziora Journal: J Thorac Dis Date: 2022-01 Impact factor: 3.005
Authors: Michal Pasierski; Jakub Staromłyński; Janina Finke; Radoslaw Litwinowicz; Grzegorz Filip; Adam Kowalówka; Wojciech Wańha; Michalina Kołodziejczak; Natalia Piekuś-Słomka; Andrzej Łoś; Sebastian Stefaniak; Wojciech Wojakowski; Marek Jemielity; Jan Rogowski; Marek Deja; Dariusz Jagielak; Krzysztof Bartus; Silvia Mariani; Tong Li; Matteo Matteucci; Daniele Ronco; Federica Jiritano; Dario Fina; Gennaro Martucci; Paolo Meani; Giuseppe Maria Raffa; Artur Słomka; Pietro Giorgio Malvidni; Roberto Lorusso; Michal Zembala; Piotr Suwalski; Mariusz Kowalewski Journal: Front Cardiovasc Med Date: 2022-06-15
Authors: Mariusz Kowalewski; Marek Jasiński; Jakub Staromłyński; Marian Zembala; Kazimierz Widenka; Michał Oskar Zembala; Krzysztof Bartuś; Tomasz Hirnle; Inga Dziembowska; Piotr Knapik; Marek Deja; Waldemar Wierzba; Zdzisław Tobota; Bohdan J Maruszewski; Piotr Suwalski Journal: J Clin Med Date: 2020-05-04 Impact factor: 4.241